TMCnet News
Aquinox to Present at 2018 UBS Global Healthcare ConferenceVANCOUVER, British Columbia, May 16, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, announced today that David Main, President & CEO, will provide a corporate update at the upcoming 2018 UBS Global Healthcare Conference in New York on Wednesday, May 23rd 2018. Aquinox Presentation Details Date: Wednesday, May 23rd 2018 A live webcast and archive of the event will be available at: https://cc.talkpoint.com/ubsx001/052118a_as/?entity=75_XVWH8N7 About Aquinox Pharmaceuticals, Inc. Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics for chronic urological conditions marked by inflammation and pain. Aquinox's lead drug candidate, rosiptor (AQX-1125), is in Phase 3 development for the treatment of patients with interstitial cystitis/bladder pain syndrome (IC/BPS), a condition for which there are currently few FDA approved and/or effective treatment options. Aquinox is focused on leveraging its library of novel compounds that activate SHIP1 to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. For more information, please visit http://www.aqxpharma.com/. Investor Contact Info: Brendan Payne Associate Director, Investor Relations Gitanjali Ogawa |